Merck beats estimates and lifts its profit outlook as Keytruda tops forecasts

Merck (MRK) beat third-quarter estimates on Thursday October 29 and raised its 2026 adjusted profit outlook. Keytruda, its cancer immunotherapy, brought in $8.6 billion, well above what analysts expected. Qlex, the newer under-the-skin version of the drug, had its best quarter since launch. John Hickenlooper holds Merck as a long position.

Sources

Merck Beats Q3 and Raises 2026 Profit Outlook as Keytruda Hits $8.6B and Injectable Qlex Surges to $830M Ahead of 2028 Patent Cliff
The whole story · updated
CN
CNBC
·
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength

The whole feed is waiting

Sign in to read every post and follow wallets.
Sign in